Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial

H Saeki, N Baba, K Ito, D Yokota, H Tsubouchi, H Saeki, N Baba, K Ito, D Yokota, H Tsubouchi

Abstract

Background: In atopic dermatitis (AD), phosphodiesterase 4 (PDE4) inhibition reduces proinflammatory mediators and cytokines. Difamilast is a new selective PDE4 inhibitor.

Objectives: To demonstrate the superiority of topical difamilast to vehicle in Japanese paediatric patients with AD.

Methods: This was a phase III randomized, double-blind, vehicle-controlled trial. Patients aged 2-14 years with an Investigator Global Assessment (IGA) score of 2 or 3 received difamilast 0·3% (n = 83), difamilast 1% (n = 85) or vehicle (n = 83) ointment twice daily for 4 weeks.

Results: The primary endpoint was the percentage of patients with an IGA score of 0 or 1 with improvement by at least two grades at week 4. The success rates in IGA score at week 4 were 44·6%, 47·1% and 18·1% in the difamilast 0·3%, difamilast 1% and vehicle groups, respectively. Both difamilast groups demonstrated significantly higher success rates in IGA score compared with vehicle at week 4 [difamilast 0·3% (P < 0·001); difamilast 1% (P < 0·001)]. Regarding secondary endpoints, improvements in Eczema Area and Severity Index (EASI; improvement of ≥ 50%, ≥ 75% and ≥ 90% in overall score) at week 4 were significantly higher in patients in the difamilast 0·3% and 1% groups than those in the vehicle group. EASI score in the difamilast 0·3% and 1% groups was significantly reduced compared with that of patients in the vehicle group at week 1. The significant difference between both the difamilast groups and the vehicle groups was maintained from week 1 through to week 4. Most treatment-emergent adverse events were mild or moderate, and no serious events or deaths were reported.

Conclusions: Difamilast 0·3% and 1% ointments are superior to vehicle and well tolerated in Japanese paediatric patients with AD.

Trial registration: ClinicalTrials.gov NCT03911401.

© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Figure 1
Figure 1
Patient disposition throughout the phases of the trial.
Figure 2
Figure 2
Success rate in Investigator’s Global Assessment (IGA) score. The data represent the percentage of patients achieving an IGA score of 0 or 1 with an improvement of at least two grades at each timepoint. All timepoints: vehicle, n = 83; difamilast 0·3%, n = 83; difamilast 1%, n = 85. P‐values are for the comparison between each difamilast group and the vehicle group.
Figure 3
Figure 3
Success rate in Eczema Area and Severity Index (EASI) 50, EASI 75 and EASI 90 at week 4. The data represent the percentage of patients achieving ≥ 50% (EASI 50), ≥ 75% (EASI 75) and ≥ 90% (EASI 90) improvement in overall EASI score at week 4. Vehicle, n = 83; difamilast 0·3%, n = 83; difamilast 1%, n = 85. P‐values are for the comparison between each difamilast group and the vehicle group.
Figure 4
Figure 4
Least squares (LS) mean percentage change in overall Eczema Area and Severity Index (EASI) score from baseline at each timepoint. Week 1: vehicle, n = 81; difamilast 0·3%, n = 83; difamilast 1%, n = 85. Week 2: vehicle, n = 70; difamilast 0·3%, n = 82; difamilast 1%, n = 81. Week 4: vehicle, n = 59; difamilast 0·3%, n = 77; difamilast 1%, n = 77. P‐values are for the comparison between each difamilast group and the vehicle group. *P < 0·001.
Figure 5
Figure 5
Least squares (LS) mean change in Verbal Rating Scale (VRS) for pruritus score from baseline at each timepoint. Week 1: vehicle, n = 40; difamilast 0·3%, n = 42; difamilast 1%, n = 43. Week 2: vehicle, n = 37; difamilast 0·3%, n = 42; difamilast 1%, n = 42. Week 4: vehicle, n = 33; difamilast 0·3%, n = 38; difamilast 1%, n = 41. P‐values are for the comparison between each difamilast group and the vehicle group. *P < 0·05; **P < 0·01; ***P < 0·005.

References

    1. Roduit C, Frei R, Depner M et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr 2017; 171:655–62.
    1. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109–22.
    1. Drucker AM, Wang AR, Li WQ et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017; 137:26–30.
    1. Weidinger S, Beck LA, Bieber T et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4:1.
    1. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71:116–32.
    1. Katayama I, Aihara M, Ohya Y et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int 2017; 66:230–47.
    1. Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology 2017; 233:333–43.
    1. Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatolog Treat 2016; 27:568–76.
    1. Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol 2018; 78:S43–S52.
    1. Ahluwalia J, Udkoff J, Waldman A et al. Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook. Drugs 2017; 77:1389–97.
    1. Malajian D, Guttman‐Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015; 73:311–18.
    1. Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol 2017; 18:837–43.
    1. Hiyama H, Arichika N & Sakurai K Pharmacological activity of difamilast, a novel PDE4 inhibitor for the topical treatment of atopic dermatitis: comparison with other PDE4 inhibitors. Presented at the American Academy of Dermatology Annual Meeting, Washington, DC, USA, 1–5 March 2019.
    1. Eichenfield LF, Rosenberg N, Roth S et al. Efficacy and safety of difamilast, a topical PDE4 inhibitor, in a phase 2 study of pediatric patients with atopic dermatitis. Presented at: American Academy of Dermatology Annual Meeting, Washington, DC, USA, 1–5 March 2019.
    1. Hanifin JM, Ellis CN, Frieden IJ et al. OPA‐15406, a novel, topical, nonsteroidal, selective phosphodiesterase‐4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase‐II randomized, double‐blind, placebo‐controlled study. J Am Acad Dermatol 2016; 75:297–305.
    1. Saeki H, Baba N, Oshiden K et al. Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis. J Dermatol 2020; 47:17–24.
    1. Saeki H, Kawashima M, Sugaya S et al. Efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double‐blind, placebo‐controlled study. J Dermatol 2019; 46:672–9.
    1. Japanese Dermatological Association . Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018. Available at: (last accessed 9 September 2021) (in Japanese).
    1. Futamura M, Leshem YA, Thomas KS et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74:288–94.
    1. Mosteller RD. Simplified calculation of body‐surface area. N Engl J Med 1987; 317:1098.
    1. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10:11–18.
    1. Phan NQ, Blome C, Fritz F et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92:502–7.
    1. Charman CR, Venn AJ, Ravenscroft JC et al. Translating Patient‐Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor‐based methods. Br J Dermatol 2013; 169:1326–32.
    1. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol 2018; 19:319–32.
    1. Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. J Clin Med 2015; 4:231–42.
    1. Fenner J, Silverberg NB. Skin diseases associated with atopic dermatitis. Clin Dermatol 2018; 36:631–40.
    1. Furue M, Yamazaki S, Jimbow K et al. Prevalence of dermatological disorders in Japan: a nationwide, cross‐sectional, seasonal, multicenter, hospital‐based study. J Dermatol 2011; 38:310–20.
    1. Paller AS, Tom WL, Lebwohl MG et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494–503.
    1. . Long‐term trial of OPA‐15406 ointment in adult and pediatric patients with atopic dermatitis. Available at: (last accessed 27 November 2020).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する